Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 9th Preview)
-
Hepatitis D late-stage readout
Vir Biotechnology reported the first results from a pivotal hepatitis D program, saying tobevibart plus a companion regimen hit the primary endpoint in the first late-stage study of chronic hepatitis D. The company disclosed that 44% of treated patients achieved the trial’s key response measure, advancing the combination toward additional late-stage milestones. The report adds incremental competition to a crowded treatment landscape where Gilead and Mirum have built momentum with hepatitis D efforts. For clinicians and payers, it also sharpens expectations for dosing cadence and response rates that may shape future guideline positioning. Vir emphasized the result as a first pivotal validation rather than a full program readout. Additional studies are expected to further confirm durability and safety in larger cohorts before any regulatory pathway becomes clearer.
-
Immunology R&D setback
Sanofi abruptly stopped development of a key early-stage immunology degrader program with Nurix, ending work on SAR448272 (NX-3911), a STAT6 degrader in a Phase I study. Nurix said the collaboration remains in place for other targets and programs, but investors punished the news, sending the stock down sharply. The termination also interrupts an ongoing European Phase I effort that had begun recruitment in Germany and planned broader expansion across additional countries. The halted program had been positioned within a multi-year protein degradation collaboration between the two companies. For the sector, the move underscores how early clinical readouts and evolving risk assessments can quickly reshape platform portfolios—even when overall cash runway and other clinical assets remain unchanged.
-
Autoimmune cell therapy first-in-human update
Nkarta said it will present first human data for its NK-cell therapy across two autoimmune indications—myositis and systemic sclerosis—highlighting safety and early signs of activity. The company’s upcoming disclosure is positioned as a key early validation point for an expanding class of immune-resetting approaches. The update matters because autoimmune cell therapies often face tight early safety constraints while requiring credible functional engagement of target immune pathways. Nkarta is betting that natural killer-cell biology can modulate dysregulated immune circuits without broad systemic immunosuppression. Investors and clinicians will focus on dose levels, adverse-event patterns, and any signal of clinical meaningfulness as the program progresses beyond initial cohorts.
-
Cancer therapy resistance – ferroptosis linkage
Researchers reported mechanistic work in pancreatic ductal adenocarcinoma showing that combining SRRM1 targeting with ferroptosis inducers can overcome gemcitabine resistance in preclinical models. The study, published in Cancer & Metabolism, ties SRRM1 elevation to advanced disease features and worse survival in patient cohorts. In cell lines, clinical tissue cohorts, and mouse xenografts, SRRM1 depletion was shown to re-sensitize refractory tumors to gemcitabine by disinhibiting ferroptotic cell death pathways. The authors describe a mechanistic bridge between RNA splicing regulation, redox homeostasis, and chemotherapeutic responsiveness. For oncology development, the work provides a rationale for exploring SRRM1 as a biomarker-and-combination target, particularly where gemcitabine durability has been limited by resistance and microenvironmental constraints.
-
Cancer therapy resistance – cisplatin and bladder cancer
A bladder cancer study identified mitochondrial translation release factor MTRF1 as a suppressor of cisplatin resistance, linking restoration of MTRF1 to ferroptosis vulnerability. Published in Cell Death Discovery, the work suggests that resistant cell models have lower MTRF1 levels, and that bringing MTRF1 back reduces IC50 values and suppresses multiple malignant phenotypes. Mechanistically, the researchers report changes in canonical ferroptosis markers—higher intracellular iron and lipid peroxidation signals, increased ACSL4, and reduced GPX4 and SLC7A11—alongside an interaction between MTRF1 and the mitochondrial transporter SLC25A5. They also describe a pathway where MTRF1 promotes ubiquitin-proteasome degradation of SLC25A5 via OTUB1 displacement. The preclinical data position MTRF1 as both a potential biomarker and a target to improve cisplatin durability in advanced bladder cancer settings.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.